Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Facultad de Farmacia y Bioquímica, Junín 956, C1113AAD, Buenos Aires, Argentina.
Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Facultad de Farmacia y Bioquímica, Junín 956, C1113AAD, Buenos Aires, Argentina.
Int J Biochem Cell Biol. 2019 Sep;114:105575. doi: 10.1016/j.biocel.2019.105575. Epub 2019 Jul 27.
Photodynamic therapy (PDT) is a highly specific and clinically approved method for cancer treatment in which a nontoxic drug known as photosensitizer (PS) is administered to a patient. After selective tumor irradiation, an almost complete eradication of the tumor can be reached as a consequence of reactive oxygen species (ROS) generation, which not only damage tumor cells, but also lead to tumor-associated vasculature occlusion and the induction of an immune response. Despite exhaustive investigation and encouraging results, zinc(II) phthalocyanines (ZnPcs) have not been approved as PSs for clinical use yet. This review presents an overview on the physicochemical properties of ZnPcs and biological results obtained both in vitro and in more complex models, such as 3D cell cultures, chicken chorioallantoic membranes and tumor-bearing mice. Cell death pathways induced after PDT treatment with ZnPcs are discussed in each case. Finally, combined therapeutic strategies including ZnPcs and the currently available clinical trials are mentioned.
光动力疗法（PDT）是一种高度特异和临床认可的癌症治疗方法，其中将一种称为光敏剂（PS）的无毒药物施用于患者。在选择性肿瘤照射后，由于活性氧（ROS）的产生，可以达到几乎完全消除肿瘤的效果，这不仅会损伤肿瘤细胞，还会导致肿瘤相关血管阻塞和免疫反应的诱导。尽管进行了详尽的研究并取得了令人鼓舞的结果，但锌（II）酞菁（ZnPcs）尚未被批准为临床使用的 PS。这篇综述介绍了 ZnPcs 的物理化学性质以及在体外和更复杂模型（如 3D 细胞培养物、鸡胚绒毛尿囊膜和荷瘤小鼠）中获得的生物学结果。在每种情况下，都讨论了 PDT 治疗后诱导的细胞死亡途径。最后，提到了包括 ZnPcs 和当前可用临床试验在内的联合治疗策略。
